Alcobra Ltd. (NASDAQ:ADHD) has received a consensus rating of “Hold” from the ten ratings firms that are presently covering the company. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $5.17.
A number of equities analysts have commented on ADHD shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $16.00 price target on shares of Alcobra in a research note on Thursday. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Alcobra in a research note on Tuesday, June 21st. Canaccord Genuity started coverage on Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating on the stock. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Alcobra in a research note on Thursday, September 1st. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Alcobra in a research note on Thursday, August 25th.
Shares of Alcobra (NASDAQ:ADHD) traded up 3.64% during trading on Monday, hitting $2.56. The company had a trading volume of 337,189 shares. The company’s 50 day moving average is $4.69 and its 200 day moving average is $4.50. Alcobra has a 1-year low of $1.95 and a 1-year high of $8.78. The firm’s market capitalization is $70.56 million.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. Analysts anticipate that Alcobra will post ($0.94) earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in ADHD. Stifel Financial Corp increased its stake in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares during the period. Jefferies Group LLC bought a new stake in Alcobra during the second quarter valued at approximately $533,000. Palo Alto Investors LLC increased its stake in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the period. BlackRock Fund Advisors increased its stake in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock valued at $1,344,000 after buying an additional 36,218 shares during the period. Finally, VHCP Management LLC increased its position in shares of Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. 73.69% of the stock is currently owned by institutional investors and hedge funds.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.